Aarti Drugs (India) Performance
| AARTIDRUGS | 460.80 2.40 0.52% |
The firm shows a Beta (market volatility) of 0.23, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Aarti Drugs' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aarti Drugs is expected to be smaller as well. At this point, Aarti Drugs Limited has a negative expected return of -0.37%. Please make sure to confirm Aarti Drugs' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Aarti Drugs Limited performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aarti Drugs Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Forward Dividend Yield 0.0022 | Payout Ratio 0.0604 | Last Split Factor 4:1 | Forward Dividend Rate 1 | Ex Dividend Date 2024-02-06 |
1 | Aarti Drugs shares trade lower after 7 observations from USFDA - Moneycontrol | 09/23/2024 |
2 | Aarti Drugs Receives Sell Rating from MarketsMOJO, Poor Growth and Bearish Trend Indicate Downgrade - MarketsMojo | 11/14/2024 |
| Begin Period Cash Flow | 75 M |
Aarti |
Aarti Drugs Relative Risk vs. Return Landscape
If you would invest 58,270 in Aarti Drugs Limited on September 3, 2024 and sell it today you would lose (12,190) from holding Aarti Drugs Limited or give up 20.92% of portfolio value over 90 days. Aarti Drugs Limited is generating negative expected returns and assumes 0.9934% volatility on return distribution over the 90 days horizon. Simply put, 8% of stocks are less volatile than Aarti, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Aarti Drugs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aarti Drugs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aarti Drugs Limited, and traders can use it to determine the average amount a Aarti Drugs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3694
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AARTIDRUGS |
Estimated Market Risk
| 0.99 actual daily | 8 92% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.37 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aarti Drugs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aarti Drugs by adding Aarti Drugs to a well-diversified portfolio.
Aarti Drugs Fundamentals Growth
Aarti Stock prices reflect investors' perceptions of the future prospects and financial health of Aarti Drugs, and Aarti Drugs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aarti Stock performance.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0617 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 47.73 B | ||||
| Shares Outstanding | 91.27 M | ||||
| Price To Book | 3.29 X | ||||
| Price To Sales | 1.77 X | ||||
| Revenue | 25.09 B | ||||
| Gross Profit | 8.06 B | ||||
| EBITDA | 3.25 B | ||||
| Net Income | 1.71 B | ||||
| Total Debt | 5.64 B | ||||
| Book Value Per Share | 139.96 X | ||||
| Cash Flow From Operations | 3.59 B | ||||
| Earnings Per Share | 16.59 X | ||||
| Total Asset | 24.32 B | ||||
| Retained Earnings | 11.55 B | ||||
About Aarti Drugs Performance
Assessing Aarti Drugs' fundamental ratios provides investors with valuable insights into Aarti Drugs' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aarti Drugs is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Aarti Drugs is entity of India. It is traded as Stock on NSE exchange.Things to note about Aarti Drugs Limited performance evaluation
Checking the ongoing alerts about Aarti Drugs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aarti Drugs Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aarti Drugs Limited generated a negative expected return over the last 90 days | |
| Aarti Drugs Limited is unlikely to experience financial distress in the next 2 years | |
| About 62.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Aarti Drugs Receives Sell Rating from MarketsMOJO, Poor Growth and Bearish Trend Indicate Downgrade - MarketsMojo |
- Analyzing Aarti Drugs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aarti Drugs' stock is overvalued or undervalued compared to its peers.
- Examining Aarti Drugs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aarti Drugs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aarti Drugs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aarti Drugs' stock. These opinions can provide insight into Aarti Drugs' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aarti Stock Analysis
When running Aarti Drugs' price analysis, check to measure Aarti Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarti Drugs is operating at the current time. Most of Aarti Drugs' value examination focuses on studying past and present price action to predict the probability of Aarti Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarti Drugs' price. Additionally, you may evaluate how the addition of Aarti Drugs to your portfolios can decrease your overall portfolio volatility.